Ariel Hourvitz

TL;DR: Ovarian stimulation with letrozole and FSH appears to be a cost-effective alternative for fertility preservation in breast cancer patients with reduced estrogen exposure, compared with standard IVF.

TL;DR: The role(s) of estrogens will be examined not only by analyzing the physiological evidence to the effect that these hormones control ovarian function and follicular growth, but also by summarizing the molecular evidence for the existence and distribution of the cognate receptors.

TL;DR: It is suggested that IVM during the luteal phase can be offered to patients as an optional treatment for urgent fertility preservation when there is insufficient time for conventional follicular phase oocyte retrieval before chemotherapy must be initiated.

TL;DR: In breast cancer patients, co-administration of tamoxifen during conventional COH for fertility preservation does not interfere with IVF results, and the high serum E2 levels during COH should be considered safe, as it simulates the high prevalence of persistently high serumE2 levels in premenopausal Breast cancer patients safely treated with adjuvant tamoxIFen.

TL;DR: Patients conceived through oocyte donation have an increased risk for placental complications of pregnancy and these findings support the 'immunologic theory' suggesting that immunologic intolerance between the mother and the fetus may play an important role in the pathogenesis of preeclampsia.